Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

YUPELRI ® Collaboration Revenue increased 15% year-over-year 1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation relating to YUPELRI ® has been resolved following settlement with Mankind Pharma in March